HLA-C and neoplasm: These tumour-specific mutant proteins can be processed into short peptides (epitopes) and presented on the surface of tumour cells in the context of major histocompatibility complex (MHC), human leukocyte antigen (HLA) in humans, leading to their immune recognition by T-cells as foreign antigens.